EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making

Rachel Hellemans, Liset H M Pengel iD, Sylvain Choquet, Umberto Maggiore iD, for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project

Transplant International · 2021-10 · 34 (10) · 1789-1800

DOI: 10.1111/tri.13952 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant International, online erschienen am 27.09.2021. Verfasst von Rachel Hellemans und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Antwerp University Hospital, Edegem, Belgium. Hauptthemen laut MEDLINE: Kidney Transplantation, Skin Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationSkin NeoplasmsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

cancerimmunosuppressionkidney transplantationmTORirejection

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Nephrology, Antwerp University Hospital, Edegem, Belgium.
  • Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Edegem, Belgium.
  • Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Service d'Hématologie, Hôpital Pitié Salpêtrière, Paris, France.
  • Nephrology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

ORCID-Profile: Liset H M Pengel, Umberto Maggiore

Zitieren

APA

Hellemans, R., Pengel, L. H. M., Choquet, S., Maggiore, U., & for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project (2021). Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making. Transplant International, 34(10), 1789-1800. https://doi.org/10.1111/tri.13952

Vancouver

Hellemans R, Pengel LHM, Choquet S, Maggiore U, for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project. Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making. Transplant International. 2021;34(10):1789-1800. doi:10.1111/tri.13952

BibTeX
@article{Hellemans2021,
  author = {Hellemans, Rachel and Pengel, Liset H M and Choquet, Sylvain and Maggiore, Umberto and for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project, for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project},
  title = {Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making},
  journal = {Transplant International},
  year = {2021},
  volume = {34},
  number = {10},
  pages = {1789--1800},
  doi = {10.1111/tri.13952}
}
Kostenlos starten →